. 2018 Feb 8;16(2):453–506. doi: 10.11124/JBISRIR-2016-003185

Table 5.

Results for studies reporting excess arm volume (ml)

Study	Method	Number of participants (n)	Pre-intervention EAV	Post-interventionEAV	Final reportedEAV
*Complex decongestive treatment (CDT/DLT)*
Dayes et al. 2013³⁵^,^aDLT group^b^,^cControl group^b^,^c	Manual circumference measurement	3123	23% ± 1221% ± 7	17% ± 12^e12% ± 12^e	15% ± 15^e15% ± 13^e
Gradalski et al. 2015⁸²CDT group^b^,^dCB group	Manual circumference measurement	25^‡	898 ± 445^‡	472 ± 285^e^,^f ^‡	506 ± 263^e ^‡
Hwang et al. 2013⁷⁹CDT group 1 (<20%EAV)^b^,^dCDT group 2 (≥20%EAV)	Perometer	32^‡	11% ± 5^‡	10% ± 9^g ^‡	14% ± 11^g ^‡

EAV = excess arm volume.

^‡Data not presented: mean breast cancer-related lymphedema (BCRL) duration >9 months.

^aData provided by corresponding author.

^bData presented as relative (%) EAV, i.e. Inline graphic .

^cSubgroup of women with BCRL duration <12months.

^dMean BCRL duration ≤9 months.

^ep > .05 between group difference.

^fp < .05 within group difference.

^gNo p values reported.